Pirfenidone capsules for silicosis or coal dust lung disease
Treatments studied
Part of Lungs & breathing clinical trials.
This Phase 3 trial tests whether pirfenidone slows or improves lung damage in people with silicosis or coal worker’s pneumoconiosis. It looks at both effectiveness and side effects, and uses lung function tests and lung scans to track changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 70 years old
- Have been diagnosed with silicosis or coal worker’s pneumoconiosis from occupational exposure
- Have lung test results showing moderate lung restriction: FVC between 40% and 79% predicted, and DLCO between 30% and 79% predicted
- Your CT lung scan (HRCT) must show widespread (diffuse) scarring-type interstitial lung changes
- Be able to understand the study and sign informed consent
- In the last 4 weeks, you should not have had infections like pneumonia or other serious lung infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a modified Chinese herbal formula (Qing-Zao-Jiu-Fei Decoction) to see if it helps people with pneumoconiosis, a lung disease caused by inhaling dust. You would take the herbal medicine and have regular check-ups to see how your lungs respond.
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
This study tests a new medication called AK3280 for people with idiopathic pulmonary fibrosis (IPF), a lung condition. The goal is to see if AK3280 can help improve lung function. To join, you must have a confirmed IPF diagnosis and meet certain health criteria.
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
This trial tests if pirfenidone capsules can help treat lung damage caused by radiation therapy, with or without immune-related pneumonia. It may be suitable for people with mild to moderate lung function impairment who have recently developed radiation lung injury.
This Phase 3 trial tests whether pirfenidone can prevent or reduce lung scarring (fibrosis) in adults with ARDS who are within about a week of their illness starting. It may help by lowering harmful inflammation and the body’s scarring response.
Hear when a new Pneumoconiosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.